You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Opus Genetics, Inc. and Ashwath Jayagopal agreed that Jayagopal will transition from Chief Scientific and Development Officer effective October 19, 2026 and provide six months of consulting services at $250 per hour; his vested options will remain exercisable during the arrangement.
Opus Genetics expects a $10 million milestone this quarter following FDA approval of a Viatris-partnered presbyopia eye drop, with runway into 2029. Its LCA5 trial is dosing, while another trial enrolled 11 patients.
Opus Genetics reported improved retinal sensitivity in three of four evaluable OPGx-BEST1 participants (75%), sustained OPGx-LCA5 visual improvements through 24 months in adults, and expects Phase 3 OPGx-LCA5 dosing in the fourth quarter of 2026.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Illustrative technical + ownership context — a signal mix, not investment advice.
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IRD
this stock
Opus Genetics, Inc.
|
$326.96M | +112.4% | +29.1% | — | 16.0% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$139.20B | +21.1% | +46.2% | 35.4 | 1.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$98.29B | +20.6% | +20.8% | 21.0 | 2.1% |
|
MRNA
Moderna, Inc.
|
$91.20B | +776.2% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$66.49B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Opus Genetics, Inc. and Ashwath Jayagopal agreed that Jayagopal will transition from Chief Scientific and Development Officer effective October 19, 2026 and provide six months of consulting services at $250 per hour; his vested options will remain exercisable during the arrangement.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IRD | +16.0% | -3.2% | -14.1% | +16.4% | +112.4% |
| SPY | -0.7% | -1.3% | +2.5% | +1.5% | +12.5% |
| vs SPY | +16.7% | -1.8% | -16.6% | +14.9% | +100.0% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
